Supplementary Table II (online only).

The number of COVID-19 patients with symptomatic venous thromboembolism (VTE) according to the anticoagulation regimen and admission to intensive care unit (ICU)

	Ward	Transferred to ICU	Admitted to ICU	Totally
Prophylactic LMWH	0/4 (0)	0/0	0/0	0/4 (0)
Intermediate LMWH	3/116 (2.6)	3/12 (25)	0/1 (0)	6/129 (4.7)
Therapeutic LMWH	0/20 (0)	3/10 (30)	2/5 (40)	5/35 (14.3)
Totally	3/140 (2.1)	6/22 (27.3)	2/6 (33.3)	11/168 (6.5)

The figures represent the number of patients with confirmed symptomatic VTE divided by the number of patients within a specific subgroup (percentage). Totally 140 patients were admitted to the ward and never transferred to the ICU; 22 patients were admitted to the ward and further transferred to the ICU due to deterioration; 6 patients were admitted initially to the ward with severe disease. Intermediate LMWH: Subcutaneous enoxaparin 80 mg once daily; Prophylactic low-molecular-weight heparin (LMWH): subcutaneous enoxaparin 40 mg once daily; Therapeutic LMWH: subcutaneous enoxaparin 1 mg/kg twice daily.